文献速递耳科与耳神经

测量慢性咽鼓管功能障碍的健康效用

Measuring the health utility of chronic eustachian tube dysfunction.
PubMed 文献 · Laryngoscope · 2019-03-22

前瞻性研究纳入2017年4月至2018年7月三级诊所53例慢性咽鼓管功能障碍患者,采用ETDQ-7及EQ-5D-3L、VAS、TTO、SG评估健康效用,分为药物治疗组34例与鼓膜切开±置管组19例,治疗前后ETDQ-7(P=0.001)和TTO(P=0.011)评分有显著变化。

要点

  • 慢性咽鼓管功能障碍对生活质量有显著负担,健康效用与胃食管反流病和中度哮喘相似。
  • 不同测量方法所得健康效用不同:EQ-5D-3L 0.90±0.11、VAS 0.76±0.21、TTO 0.85±0.23、SG 0.94±0.11(P<.001)。
  • 治疗后仅TTO评分有显著变化(P=.011),ETDQ-7评分也有显著变化(P=.001)。

核心结论

  • 慢性咽鼓管功能障碍对生活质量有显著负担,健康效用与胃食管反流病和中度哮喘相似。
  • 尽管疾病特异性生活质量量表可测得治疗相关变化,但治疗后仅TTO有显著变化。
  • 健康效用似乎取决于测量方法,但为评估咽鼓管功能障碍管理创新的成本效果提供了基准。

研究设计与样本

  • 前瞻性研究,纳入2017年4月至2018年7月从三级诊所招募的53例慢性咽鼓管功能障碍患者。
  • 使用ETDQ-7问卷,并采用EQ-5D-3L、VAS、TTO和SG评估健康效用。
  • 参与者分为药物治疗组或手术操作组,一周随访重复健康效用测量和ETDQ-7。

主要发现

  • 53例患者纳入最终分析,其中34例接受药物治疗,19例接受鼓膜切开±PE管置入。
  • 基线ETDQ-7均值为4.26±1.31。
  • 健康效用测量值因方法不同而异:EQ-5D-3L 0.90±0.11;VAS 0.76±0.21;TTO 0.85±0.23;SG 0.94±0.11(P<.001)。
  • 治疗后ETDQ-7(P=.001)和TTO(P=.011)评分有显著变化。
  • ETDQ-7第2题(耳痛)与VAS显著相关(P=.032),第4题(感冒或鼻窦炎期间耳部症状)与TTO显著相关(P=.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the health utility of chronic Eustachian tube dysfunction (ETD). METHODS: This is a prospective study of 53 patients with chronic ETD recruited from a tertiary clinic from April 2017 to July 2018. The 7-Item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) was administered, and health utility was evaluated using the EuroQol-5 Dimensions-3 Level Instrument (EQ-5D-3L), the visual analogue scale (VAS), time tradeoff (TTO), and standard gamble (SG). Participants were grouped into medical or procedural management groups. One-week follow-up included repeated health utility measures and ETDQ-7. RESULTS: Fifty-three patients were included in the final analysis. Of those, 34 were managed medically, and 19 received myringotomies ± PE tubes. The mean baseline ETDQ-7 was 4.26 ± 1.31; whereas health utility measures were different depending on the method utilized: EQ-5D-3L 0.90 ± 0.11; VAS 0.76 ± 0.21; TTO 0.85 ± 0.23; and SG 0.94 ± 0.11 (P < .001). There was a significant change in ETDQ-7 (P = .001) and TTO (P = .011) scores posttreatment. On the ETDQ-7, question 2 (pain in the ears) was significantly associated with VAS (P = .032), and question 4 (ear symptoms during a cold or sinusitis) was significantly associated with TTO (P = .006). CONCLUSION: Chronic ETD has a significant burden on quality of life, with a health utility similar to gastroesophageal reflux disease and moderate asthma. Although treatment-related changes are measurable using disease-specific quality-of-life measures, only TTO was significantly changed after treatment. Health utility seemed to depend on the method of measurement but provided a benchmark for evaluating cost-effectiveness of innovations to manage ETD. LEVEL OF EVIDENCE: 2 Laryngoscope, 130:E39-E44, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Teklu M, Kulich M, Micco AG, et al. Measuring the health utility of chronic eustachian tube dysfunction. Laryngoscope. 2019. PMID: 30900252. doi:10.1002/lary.27934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。